Retatrutide Dosage Protocol Australia: Phase 2 Dosing Schedule & Escalation Guide

Retatrutide (LY3437943) is a triple receptor agonist targeting GLP-1, GIP, and Glucagon receptors simultaneously. This triple mechanism produces stronger metabolic effects than single or dual agonists, and also means dosing must be handled with more conservative escalation to allow receptor adaptation at each level.

Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), retatrutide's glucagon receptor agonism introduces additional thermogenic and metabolic activity. The Phase 2 trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) used a stepped escalation protocol designed to minimise gastrointestinal adverse events while progressively increasing receptor engagement.

Key pharmacokinetic data Half-life: ~6 days (once-weekly subcutaneous injection) · Receptors: GLP-1R + GIPR + GcgR · Phase 2 maximum dose tested: 12mg/week · Phase 3 TRIUMPH trials: ongoing as of 2026

For full mechanistic background, see the Retatrutide Research Guide. For reconstitution and storage, see the Peptide Reconstitution & Storage Guide.

The Jastreboff et al. Phase 2 trial (NEJM, 2023) enrolled adults with obesity across four target-dose cohorts plus placebo. Cohorts targeting 4mg or higher initiated treatment at 2mg per week, a second arm initiated at 4mg, and escalated every 4 weeks; the 1mg cohort received 1mg from week 1 with no escalation. Doses were administered once weekly by subcutaneous injection.

The schedule above shows the 2mg-initiation arms. The 4mg and 8mg target cohorts each also included a faster-titration arm initiating at 4mg; the lower 2mg start was better tolerated for gastrointestinal adverse events. Escalation steps occurred every 4 weeks for up to 12 weeks, after which the target dose was maintained through week 48 (Jastreboff 2023, NEJM).

Headline efficacy The 12mg cohort reached −24.2% mean body weight reduction at 48 weeks (Jastreboff 2023, NEJM), the largest reported for any GLP-1-class compound in a controlled trial as of 2026; lower cohorts showed dose-dependent reductions. See Retatrutide Statistics 2026 for the full per-cohort breakdown.

Graduated escalation reduces gastrointestinal adverse events by giving receptors time to adapt at each dose level. Each 4-week step corresponds to a distinct pharmacological adaptation window:

The Phase 2 protocol allowed a dose hold (staying at the current step for an additional 4 weeks if GI events were significant) and a dose reduction (stepping back one level for intolerable AEs) before re-escalation, both tools applicable to research protocol design.

RetaLABS Retatrutide is supplied lyophilised in 10mg, 20mg and 30mg vials. Standard reconstitution: add bacteriostatic water to achieve 10 mg/mL concentration.

10mg vial + 1mL bacteriostatic water = 10 mg/mL:

The 10mg vial suits low-dose research (1–4mg cohorts) and the early 2mg escalation weeks of higher cohorts. Because the vial is reconstituted to a 1mL total volume, a single 10mg vial cannot supply a full 12mg weekly dose (which needs 1.20 mL), higher-dose maintenance phases should use the 20mg or 30mg format.

20mg vial + 2mL bacteriostatic water = 10 mg/mL:

A 30mg vial + 3mL bacteriostatic water = 10 mg/mL, providing ~50% more doses at each level. Use the RetaLABS reconstitution calculator for custom concentrations. Store reconstituted solution at 2–8°C; use within 4–6 weeks. Rotate injection sites (abdomen, thigh, upper arm) weekly.

Always use bacteriostatic water BAC water contains benzyl alcohol preservative, extending reconstituted stability to 4–6 weeks at 2–8°C. Sterile water has no preservative and must be used within 24 hours of vial opening.

Key design notes from Phase 2 methodology applicable to Australian research protocols:

• Weekly interval: Retatrutide's ~6-day half-life makes once-weekly subcutaneous injection the appropriate interval. Consistent 7-day timing reduces pharmacokinetic variation.
• Dose hold: Escalation can be paused for an additional 4-week period at the current dose if GI events are significant. Holds do not constitute protocol discontinuation.
• Dose reduction: A one-step reduction (e.g. 8mg to 4mg) is permitted for intolerable AEs, with re-escalation once tolerability is re-established.
• Injection timing: No specific time-of-day requirement was used in Phase 2. Consistent weekly timing (same day each week) is standard practice.
• Body weight tracking: Phase 2 measured body weight weekly under standardised conditions (same time, fasted state).

For body composition data from Phase 2, see GLP-1 and Lean Mass Loss. For a cross-compound comparison, see Retatrutide vs Semaglutide.

Continue across the Retatrutide research cluster: Retatrutide Research Guide · Retatrutide Statistics 2026 · Phase 3 TRIUMPH Update · Research-grade Retatrutide.